Drugs / Febuxostat IR
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02139046 Comparator | Apr 2014 → Nov 2015 | gout | Takeda | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Febuxostat IR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02139046 ↗ |
| Route | Oral | “Febuxostat Immediate Release (IR) 40 mg over-encapsulated tablet, orally, once daily” NCT02139046 ↗ |